Similar Articles |
|
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool March 9, 2004 Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition. |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. |
The Motley Fool March 9, 2005 Steven Mallas |
CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu. |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool January 8, 2007 Matthew Crews |
CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note. |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool February 2, 2005 Alyce Lomax |
CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny. |
The Motley Fool May 5, 2004 Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways. |
The Motley Fool January 3, 2012 Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts. |
The Motley Fool January 7, 2010 Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. |
The Motley Fool October 5, 2007 Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition. |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool August 4, 2004 Phil Wohl |
CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size. |
The Motley Fool February 12, 2004 Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January. |
The Motley Fool July 6, 2007 Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers. |
The Motley Fool April 5, 2004 Dave Marino-Nachison |
Finally, Eckerd Sells J.C. Penney's drugstore operation will be split between CVS and Jean Coutu. |
The Motley Fool September 29, 2010 Andrew Bond |
Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters. |
The Motley Fool September 27, 2004 Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool June 10, 2010 Claire Stephanic |
CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers. |
The Motley Fool June 28, 2005 Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever. |
The Motley Fool July 6, 2007 Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... |
The Motley Fool December 8, 2004 Nathan Slaughter |
What's Wrong at Rite-Aid? Rite-Aid steers guidance lower after a difficult November. |
The Motley Fool March 5, 2004 Dave Marino-Nachison |
Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months. |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool May 8, 2007 Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results. |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool June 21, 2004 Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore. |
The Motley Fool May 9, 2005 Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note. |
The Motley Fool March 23, 2011 Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount. |
The Motley Fool September 26, 2006 Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? |
The Motley Fool September 21, 2006 Vitaliy Katsenelson |
Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them. |
The Motley Fool June 26, 2007 Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down. |
The Motley Fool February 4, 2008 Timothy M. Otte |
CVS Has Major Mo' Fourth-quarter results cap a stellar year for the drugstore retailer. |
The Motley Fool March 22, 2010 Dave Mock |
A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst. |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool June 14, 2010 Rich Smith |
Is CVS' $2 Billion Buyback Good Medicine? Don't assume just because CVS is buying its stock, that this is a good idea. |
The Motley Fool January 3, 2006 Stephen D. Simpson |
Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures. |
The Motley Fool December 23, 2003 Dave Marino-Nachison |
Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years. |
The Motley Fool August 8, 2005 Mike Cianciolo |
A Cautiously Optimistic CVS The retail pharmacy nudges guidance up after an impressive quarter. All things considered, the outlook seems bright for investors in this company. |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool December 16, 2003 W.D. Crotty |
Don't Jump Off Pier 1 Shares of Pier 1 plunged nearly 10.4% on disappointing third-quarter results. There are some positive signs for the stock, including a new spokesperson from the Fab Five. |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool November 10, 2004 Dave Marino-Nachison |
Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed. |
The Motley Fool July 7, 2004 Steven Mallas |
CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be. |
The Motley Fool June 25, 2004 Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |